Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed/Refractory Follicular Lymphoma: Results from the Phase 1/2 BRUIN Study

被引：3

作者：

Shah, Nirav N. ^{[1
]}

Zinzani, Pier Luigi ^{[2
]}

Wang, Michael L. ^{[3
]}

Nasta, Sunita D. ^{[4
]}

Lech-Maranda, Ewa ^{[5
]}

Ogawa, Yoshiaki ^{[6
]}

Fakhri, Bita ^{[7
]}

Kuss, Bryone ^{[8
,9
]}

Miyashita, Kaname ^{[10
]}

Patel, Krish ^{[11
]}

Coombs, Catherine C. ^{[12
]}

Ma, Shuo ^{[13
]}

Patel, Manish ^{[14
]}

Barve, Minal A. ^{[15
]}

Tessoulin, Benoit ^{[16
,17
]}

Stathis, Anastasios ^{[18
]}

Kim, Won Seog ^{[19
]}

Ennishi, Daisuke

Hashimoto, Daigo ^{[20
,21
]}

Kojima, Kensuke ^{[22
]}

Zelenetz, Andrew D. ^{[23
]}

Cohen, Jonathon B. ^{[24
]}

Vose, Julie M. ^{[25
]}

Maddocks, Kami J. ^{[26
]}

Munir, Talha ^{[27
]}

Sun, Fangfang ^{[28
]}

Bian, Faith ^{[28
]}

Tsai, Donald E. ^{[29
]}

Abada, Paolo ^{[29
]}

Cheah, Chan Y. ^{[30
,31
]}

机构：

[1] Med Coll Wisconsin, Milwaukee, WI USA

[2] Univ Bologna, Inst Hematol Seragnoli, Bologna, Italy

[3] Texas MD Anderson Canc Ctr, Houston, TX USA

[4] Univ Penn, Abramson Canc Ctr, Philadelphia, PA USA

[5] Inst Hematol & Transfus Med, Warsaw, Poland

[6] Tokai Univ, Sch Med, Hiratsuka, Kanagawa, Japan

[7] Stanford Univ, Sch Med, Stanford, CA USA

[8] Flinders Med Ctr, Bedford Pk, Australia

[9] Flinders Univ S Australia, Bedford Pk, Australia

[10] Natl Hosp Org Kyushu Canc Ctr, Fukuoka, Japan

[11] Swedish Canc Inst, Seattle, WA USA

[12] Univ Calif Irvine, Irvine, CA USA

[13] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL USA

[14] Florida Canc Specialists, Sarah Cannon Res Inst, Sarasota, FL USA

[15] Mary Crowley Canc Res, Dallas, TX USA

[16] Nantes Univ, Sch Med, Nantes, France

[17] Univ Hosp Nantes, Nantes, France

[18] Oncol Inst Southern Switzerland, Bellinzona, Switzerland

[19] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, South Korea

[20] Okayama Univ Hosp, Okayama, Japan

[21] Hokkaido Univ Hosp, Sapporo, Japan

[22] Kochi Med Sch Hosp, Nankoku, Japan

[23] Mem Sloan Kettering Canc Ctr, New York, NY USA

[24] Emory Univ, Winship Canc Inst, Atlanta, GA USA

[25] Univ Nebraska Med Ctr, Omaha, NE USA

[26] Ohio State Univ, Comprehens Canc Ctr, Columbus, OH USA

[27] St James Univ Hosp, Dept Haematol, Leeds, England

[28] Eli Lilly & Co, Indianapolis, IN USA

[29] Loxo Lilly, Indianapolis, IN USA

[30] Linear Clin Res, Perth, Australia

[31] Sir Charles Gairdner Hosp, Perth, Australia

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-181309

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：9

共 50 条

[1] Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Marginal Zone Lymphoma: Results from Phase 1/2 BRUIN Study
Patel, Krish
Vose, Julie M.
Nasta, Sunita D.
Brown, Jennifer R.
Maddocks, Kami J.
Woyach, Jennifer A.
Shah, Nirav N.
Fakhri, Bita
Tessoulin, Benoit
Ma, Shuo
Jagadeesh, Deepa
Lech-Maranda, Ewa
Coombs, Catherine C.
Patel, Manish
Rhodes, Joanna M.
Ujjani, Chaitra S.
Hoffmann, Marc S.
Cheah, Chan Y.
Munir, Talha
Lewis, David
Scarfo, Lydia
Eyre, Toby A.
Alencar, Alvaro J.
Cohen, Jonathon B.
Zelenetz, Andrew D.
Tsai, Donald E.
Li, Mei
Bian, Faith
Abada, Paolo
Zinzani, Pier Luigi
BLOOD, 2023, 142
[2] Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Waldenstrom Macroglobulinemia: Results from the Phase 1/2 BRUIN Study
Palomba, M. Lia
Patel, Manish R.
Eyre, Toby A.
Jurczak, Wojciech
Lewis, David John
Gastinne, Thomas
Ma, Shuo
Cohen, Jonathon B.
Patel, Krish
Brown, Jennifer R.
Scarfo, Lydia
Munir, Talha
Lech-Maranda, Ewa
Hoffmann, Marc
Ujjani, Chaitra S.
Fakhri, Bita
Wang, Michael L.
Izutsu, Koji
Nagai, Hirokazu
Tam, Constantine S.
Seymour, John F.
Rhodes, Joanna M.
Vose, Julie M.
McKinney, Matthew
Gerson, James N.
Barve, Minal A.
Kuss, Bryone J.
Koh, Youngil
Gao, Wei
Ruppert, Amy S.
Walgren, Richard A.
Tsai, Donald E.
Nair, Binoj
Bao, Katherine
Mato, Anthony R.
Cheah, Chan Y.
BLOOD, 2022, 140
[3] Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Richter Transformation: Results from the Phase 1/2 BRUIN Study
Wierda, William G.
Lewis, David John
Ghia, Paolo
Shah, Nirav N.
Coombs, Catherine C.
Cheah, Chan Y.
Lamanna, Nicole
Rhodes, Joanna M.
Hoffmann, Marc
Ma, Shuo
Eyre, Toby A.
Munir, Talha
Patel, Manish R.
Alencar, Alvaro J.
Tam, Constantine S.
Seymour, John F.
Jurczak, Wojciech
Lech-Maranda, Ewa
Roeker, Lindsey E.
Thompson, Philip A.
Abada, Paolo B.
Wang, Chunxiao
Nair, Binoj
Liu, Hui
Tsai, Donald E.
Mato, Anthony R.
BLOOD, 2022, 140
[4] Efficacy of pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in Richter transformation: Results from the phase 1/2 BRUIN study
Rhodes, Joanna
Lewis, David
Ghia, Paolo
Shah, Nirav N.
Coombs, Catherine C.
Cheah, Chan Y.
Woyach, Jennifer
Lamanna, Nicole
Hoffmann, Marc S.
Ma, Shuo
Eyre, Toby A.
Munir, Talha
Patel, Manish R.
Alencar, Alvaro J.
Tam, Constantine S.
Seymour, John F.
Jurczak, Wojciech
Lech-Maranda, Ewa
Roeker, Lindsey E.
Thompson, Philip A.
Abada, Paolo B.
Wang, Chunxiao
Nair, Binoj
Liu, Hui
Tsai, Donald E.
Mato, Anthony R.
Wierda, William G.
CANCER RESEARCH, 2023, 83 (08)
[5] Pirtobrutinib, A Highly Selective, Non-covalent (Reversible) BTK Inhibitor In Previously Treated Mantle Cell Lymphoma: Updated Results From The Phase 1/2 BRUIN Study
Wang, Michael
Shah, Nirav
Alencar, Alvaro
Gerson, James
Patel, Manish
Fakhri, Bita
Jurczak, Wojciech
Tan, Xuan
Lewis, Katharine
Fenske, Timothy
Coombs, Catherine
Flinn, Ian
Lewis, David
Le Gouill, Steven
Palomba, M. Lia
Woyach, Jennifer
Pagel, John
Lamanna, Nicole
Cohen, Johnathon
Barve, Minal
Ghia, Paolo
Eyre, Toby
Zinzani, Pier Luigi
Ujjani, Chaitra
Koh, Youngil
Izutsu, Koji
Lech-Maranda, Ewa
Tam, Constantine
Sundaram, Suchitra
Yin, Ming
Nair, Binoj
Tsai, Donald
Balbas, Minna
Mato, Anthony
Cheah, Chan
BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 101 - 104
[6] Pirtobrutinib, a highly selective, non-covalent BTK inhibitor in Richter transformation: Results from the BRUIN study
Lewis, David John
Wierda, William G.
Ghia, Paolo
Shah, Nirav N.
Coombs, Catherine C.
Cheah, Chan Y.
Lamanna, Nicole
Rhodes, Joanna M.
Hoffmann, Marc S.
Ma, Shuo
Eyre, Toby A.
Munir, Talha
Patel, Manish R.
Alencar, Alvaro J.
Tam, Constantine S.
Seymour, John F.
Jurczak, Wojciech
Lech-Maranda, Ewa
Roeker, Lindsey E.
Thompson, Philip A.
Abada, Paolo B.
Wang, Chunxiao
Nair, Binoj
Liu, Hui
Tsai, Donald E.
Mato, Anthony R.
BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 107 - 108
[7] Pirtobrutinib, A Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Previously Treated CLL/SLL: Updated Results from the Phase 1/2 BRUIN Study
Coombs, Catherine C.
Pagel, John M.
Shah, Nirav N.
Lamanna, Nicole
Munir, Talha
Lech-Maranda, Ewa
Eyre, Toby A.
Woyach, Jennifer A.
Wierda, William G.
Cheah, Chan Y.
Cohen, Jonathon B.
Roeker, Lindsey E.
Patel, Manish R.
Fakhri, Bita
Barve, Minal A.
Tam, Constantine S.
Lewis, David
Gerson, James N.
Alencar, Alvaro
Ujjani, Chaitra
Flinn, Ian
Sundaram, Suchitra
Ma, Shuo
Jagadeesh, Deepa
Rhodes, Joanna
Taylor, Justin
Abdel-Wahab, Omar
Ghia, Paolo
Schuster, Stephen J.
Wang, Denise
Nair, Binoj
Zhu, Edward
Tsai, Donald E.
Davids, Matthew S.
Brown, Jennifer R.
Jurczak, Wojciech
Mato, Anthony R.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S268 - S269
[8] Pirtobrutinib, A Highly Selective, Non-covalent (Reversible) BTK Inhibitor In Previously Treated CLL/SLL: Updated Results From The Phase 1/2 BRUIN Study
Mato, Anthony
Pagel, John
Coombs, Catherine
Shah, Nirav
Lamanna, Nicole
Munir, Talha
Lech-Maranda, Ewa
Eyre, Toby
Woyach, Jennifer
Wierda, William
Cheah, Chan
Cohen, Johnathan
Roeker, Lindsey
Patel, Manish
Fakhri, Bita
Barve, Minal
Tam, Constantine
Lewis, David
Gerson, James
Alencar, Alvaro
Ujjani, Chaitra
Flinn, Ian
Sundaram, Suchitra
Ma, Shuo
Jagadeesh, Deepa
Rhodes, Joanna
Taylor, Justin
Abdel-Wahab, Omar
Ghia, Paolo
Schuster, Stephen
Wang, Denise
Nair, Binoj
Zhu, Edward
Tsai, Donald
Davids, Matthew
Brown, Jennifer
Jurczak, Wojciech
BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 97 - 101
[9] Efficacy of pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in relapsed/refractory Waldenstrom macroglobulinemia
Lewis, David John
Palomba, M. Lia
Patel, Manish R.
Eyre, Toby A.
Jurczak, Wojciech
Gastinne, Thomas
Ma, Shuo
Cohen, Jonathon B.
Patel, Krish
Brown, Jennifer R.
Scarfo, Lydia
Munir, Talha
Lech-Maranda, Ewa
Hoffmann, Marc S.
Ujjani, Chaitra S.
Fakhri, Bita
Wang, Michael
Izutsu, Koji
Nagai, Hirokazu
Tam, Constantine S.
Seymour, John F.
Rhodes, Joanna M.
Vose, Julie
McKinney, Matthew
Gerson, James N.
Barve, Minal A.
Kuss, Bryone
Koh, Youngil
Gao, Wei
Ruppert, Amy S.
Walgren, Richard A.
Tsai, Donald E.
Nair, Binoj
Bao, Katherine
Mato, Anthony R.
Cheah, Chan Y.
BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 109 - 110
[10] Pirtobrutinib, A Next Generation, Highly Selective, Non-covalent BTK Inhibitor In Previously Treated Mantle Cell Lymphoma: Updated Results From The Phase 1/2 BRUIN Study
Shah, Nirav N.
Alencar, Alvaro J.
Gerson, James N.
Patel, Manish R.
Fakhri, Bita
Jurczak, Wojciech
Tan, Xuan
Lewis, Katharine
Fenske, Timothy
Coombs, Catherine C.
Flinn, Ian
Lewis, David
Le Gouill, Steven
Palomba, M. Lia
Woyach, Jennifer
Pagel, John M.
Lamanna, Nicole
Cohen, Johnathon B.
Barve, Minal A.
Ghia, Paolo
Eyre, Toby A.
Mato, Anthony R.
Cheah, Chan Y.
Wang, Michael L.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 170 - 171

← 1 2 3 4 5 →